Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Fennec Pharmaceuticals, Inc. (NASDAQ: FENC).

Full DD Report for FENC

You must become a subscriber to view this report.


Recent News from (NASDAQ: FENC)

Fennec Provides Business Update and Announces First Quarter 2018 Financial Results
PEDMARK TM granted Breakthrough Therapy and Fast Track Designations by FDA Actively preparing for NDA submission later this year Strong financial position with $26.7 million in cash and no debt RESEARCH TRIANGLE PARK, N.C., May 14, 2018 (GLOBE NEWSWIRE) -- Fennec Pharmaceutical...
Source: GlobeNewswire
Date: May, 14 2018 06:00
Your Daily Pharma Scoop: Esperion Gains On Data, AnaptysBio's ANB020, Tesaro Reports Promising Data
Analysis focus: Esperion Esperion Therapeutics (ESPR) shares have moved up sharply after the company announced top-line results from a phase 2 study ( 1002-039 ) evaluating the LDL-C lowering efficacy and safety of bempedoic acid 180 mg added-on to stable background therapy of a proprotein...
Source: SeekingAlpha
Date: March, 28 2018 08:00
Fennec Pharmaceuticals receives Breakthrough Therapy designation by FDA for PEDMARK
Fennec Pharmaceuticals (NASDAQ: FENC ) announces that the FDA has granted PEDMARK (a unique formulation of sodium thiosulfate) Breakthrough Therapy designation for prevention of cisplatin-related ototoxicity in pediatric patients with standard risk hepatoblastoma (SR-HB). More news on:...
Source: SeekingAlpha
Date: March, 27 2018 07:07
Fennec Pharmaceuticals Receives Breakthrough Therapy Designation by FDA for PEDMARK(TM)
RESEARCH TRIANGLE PARK, N.C., March 27, 2018 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted PEDMARK ™ (a unique formulation of sodium thiosulfat...
Source: GlobeNewswire
Date: March, 27 2018 06:30
Fennec Provides Business Update and Announces Fiscal Year Ended December 31, 2017 Financial Results
Phase 3 SIOPEL 6 study met primary endpoint (p=0.0033) NASDAQ listing in September 2017 Two equity financings completed Strong financial position at year end with $28.3 million in cash and no debt RESEARCH TRIANGLE PARK, N.C., March 26, 2018 (GLOBE NEWSWIRE) -- Fennec Pharma...
Source: GlobeNewswire
Date: March, 26 2018 06:30
3 Things In Biotech, March 22: Sun Is In, Fennec Moving Fast, Fortress Heads Out
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotec...
Source: SeekingAlpha
Date: March, 23 2018 08:00
Your Daily Pharma Scoop: Achaogen's Plazomicin, Eiger Provides Update On Llonafarnib, Eleven Biotherapeutics Obtains Funding
Analysis focus: Achaogen Today we will discuss Achaogen (AKAO), which surged more than 10% in midday trading after providing an update on plazomicin NDA. Achaogen said that the FDA’s Antimicrobial Drugs Advisory Committee has planned a meeting to review the NDA on May 2nd, 2018. ...
Source: SeekingAlpha
Date: March, 22 2018 08:00
Fennec Pharma's Pedmark Fast Track'd in U.S. for chemo-related ear toxicity in pediatric patients with rare liver tumor; shares up 5% premarket
The FDA designates Fennec Pharmaceuticals' (NASDAQ: FENC ) PEDMARK (sodium thiosulfate) for Fast Track review for the treatment of cisplatin-related ototoxicity in pediatric patients with standard-risk hepatoblastoma, a rare liver tumor that primarily affects young children. More news ...
Source: SeekingAlpha
Date: March, 21 2018 07:39
Fennec Pharmaceuticals Receives Fast Track Designation by FDA for PEDMARK
RESEARCH TRIANGLE PARK, N.C., March 21, 2018 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted PEDMARK (a unique formulation of sodium thiosulfate) Fast Tr...
Source: GlobeNewswire
Date: March, 21 2018 06:30
Your Daily Pharma Scoop: Amgen Plans To Bring Back Cash, Roche Acquires Ignyta, Agile Tumbles On CRL
Analysis of top Seeking Alpha coverage: Amgen Today we will discuss Amgen’s ( AMGN ) plans to repatriate some of its cash holdings outside the U.S. In a SEC filing, Amgen noted that it expects to incur $6-$6.5 billion in tax expenses over time as it brings the cash back into the U...
Source: SeekingAlpha
Date: December, 26 2017 04:23

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1711.2211.0611.6010.9189,651

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-202,4983,72167.1325Short
2018-08-174,4928,71751.5315Short
2018-08-169,03921,72741.6026Short
2018-08-155,37411,47446.8363Short
2018-08-1412,80220,17763.4485Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on FENC.


About Fennec Pharmaceuticals, Inc. (NASDAQ: FENC)

Logo for Fennec Pharmaceuticals, Inc. (NASDAQ: FENC)

Fennec Pharmaceuticals Inc. is a clinical stage biotechnology company developing Sodium Thiosulfate STS , a chemo protectant against hearing loss associated with platinum based chemotherapy.

 

Contact Information

 

 

Current Management

  • Rostislav Raykov / CEO
  • Robert Andrade / CFO
  • Mark Gowland / Controller
  • Khalid Islam / Chairman, Audit Committee Member, Compensation Committee Member, Nominating Committee Member
  • Marco Brughera / Compensation Committee Member, Nominating Committee Member
    • Marco Brughera has been a director since October . He is the Global Head of the SigmaTau Rare Disease Business Unit., a position he has held since October . Currently he is also President of SigmaTau Pharmaceuticals Inc., President of SigmaTau Research Switzerland S.A. and Chief Executive Officer of SigmaTau Pharma Ltd. From January through October , Dr. Brughera held several other positions with the SigmaTau Group, including Corporate Research and Development Managing Director of SigmaTau Industrie Farmaceutiche Riunite S.p.A. From December through January , Dr. Brughera served on the Board of Directors of Gentium S.p.A., a publicly traded biopharmaceutical company. From to , Dr. Brughera served as the Vice President of Preclinical Development at Nerviano Medical Sciences S.r.l. NMS Group , a pharmaceutical oncologyfocused integrated discovery and development company. He also served as the Managing Director at Accelera S.r.l., an independent contract research organization affiliated with the NMS Group. From to , Dr. Brughera held several senior level positions in the areas of discovery and development with Pharmacia Corporation and Pfizer, Inc. Prior to , he held various positions at Pharmacia amp Upjohn Company, Inc. and Farmitalia Carlo Erba S.p.A., an Italian pharmaceutical company. Dr. Brughera earned his degree in veterinary medicine from the University of Milan and is a European Registered Toxicologist.
  • Adrian Haigh / Audit Committee Member, Nominating Committee Member
  • Chris A. Rallis / Audit Committee Member, Compensation Committee Member
  • Rostislav Raykov /

Current Share Structure

  • Market Cap: $208,651,178 - 05/16/2018
  • Issue and Outstanding: 18,464,706 - 03/16/2018

 


Recent Filings from (NASDAQ: FENC)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 14 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: May, 10 2018
Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: April, 20 2018
Notice from the SEC of registration effectiveness
Filing Type: EFFECTFiling Source: edgar
Filing Date: April, 19 2018
Post-effective amendment to an S-Type filing
Filing Type: POS AMFiling Source: edgar
Filing Date: April, 13 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: March, 29 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 28 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 28 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 23 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018

 

 


Daily Technical Chart for (NASDAQ: FENC)

Daily Technical Chart for (NASDAQ: FENC)


Stay tuned for daily updates and more on (NASDAQ: FENC)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: FENC)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in FENC is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of FENC and does not buy, sell, or trade any shares of FENC. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/